Yu-Te Huang1, Chun-Ju Lin2,3,4, Huan-Sheng Chen5, Peng-Tai Tien1,6, Chun-Ting Lai1, Ning-Yi Hsia1, Jane-Ming Lin1,7, Wen-Lu Chen1,7, Yi-Yu Tsai1,8,7. 1. Department of Ophthalmology, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, Taiwan, 40447. 2. Department of Ophthalmology, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, Taiwan, 40447. doctoraga@gmail.com. 3. School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. doctoraga@gmail.com. 4. Department of Optometry, Asia University, Taichung, Taiwan. doctoraga@gmail.com. 5. An-Shin Dialysis Center, NephroCare Ltd., Fresenius Medical Care, Taichung, Taiwan. 6. Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan. 7. Department of Optometry, Asia University, Taichung, Taiwan. 8. School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Abstract
BACKGROUND: This study evaluated the effects of dexamethasone intravitreal implant on treatment-naïve branch retinal vein occlusion (BRVO)-induced macular edema (ME), and the risk factors for earlier repeated treatment. METHODS: Patients treated from 2013 to 2016 were enrolled. The patients' demographics, medical history, best-corrected visual acuity (BCVA), and central retinal thickness (CRT) were recorded. Risk factors for repeated treatment were identified using a Cox proportional hazard model and logistic regression. RESULTS: 29 patients (mean age: 58.64 ± 13.3 years) were included; 44.8% received only one injection, while 55.2% received two or more. The mean initial CRT was 457.8 ± 167.1 μm; the peak CRT and final CRT improved significantly to 248.9 ± 57.9 μm and 329.2 ± 115.1 μm, respectively. The peak BCVA improvement and final improvement were 29.5 ± 23.5 approximate ETDRS letters and 19.8 ± 24.4 letters, respectively, with 62.1% of patients improving by more than 15 letters. Older age, higher initial CRT, and diabetes were the risk factors for multiple injections. CONCLUSION: Dexamethasone intravitreal implant results in significant peak CRT and BCVA improvements, while older age, higher initial CRT, and diabetes are risk factors for repeated injections. The optimal retreatment schedule for these patients should be further explored.
BACKGROUND: This study evaluated the effects of dexamethasone intravitreal implant on treatment-naïve branch retinal vein occlusion (BRVO)-induced macular edema (ME), and the risk factors for earlier repeated treatment. METHODS:Patients treated from 2013 to 2016 were enrolled. The patients' demographics, medical history, best-corrected visual acuity (BCVA), and central retinal thickness (CRT) were recorded. Risk factors for repeated treatment were identified using a Cox proportional hazard model and logistic regression. RESULTS: 29 patients (mean age: 58.64 ± 13.3 years) were included; 44.8% received only one injection, while 55.2% received two or more. The mean initial CRT was 457.8 ± 167.1 μm; the peak CRT and final CRT improved significantly to 248.9 ± 57.9 μm and 329.2 ± 115.1 μm, respectively. The peak BCVA improvement and final improvement were 29.5 ± 23.5 approximate ETDRS letters and 19.8 ± 24.4 letters, respectively, with 62.1% of patients improving by more than 15 letters. Older age, higher initial CRT, and diabetes were the risk factors for multiple injections. CONCLUSION:Dexamethasone intravitreal implant results in significant peak CRT and BCVA improvements, while older age, higher initial CRT, and diabetes are risk factors for repeated injections. The optimal retreatment schedule for these patients should be further explored.
Authors: Sophie Rogers; Rachel L McIntosh; Ning Cheung; Lyndell Lim; Jie Jin Wang; Paul Mitchell; Jonathan W Kowalski; Hiep Nguyen; Tien Y Wong Journal: Ophthalmology Date: 2010-02 Impact factor: 12.079